Table 1.
Characteristics of WB-samples from healthy donors and AML, ALL, CLL-patients.
| Pat.Nr | Age/Sex | Dgn. subtypes | stage | ML LC (%) | IC LC (%) | blast phenotype (CD) | Risk Stratification | WBC [G/I] | Hb [g/dl] | PLT [G/L] | Response to (induction)-chemotherapy | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AML | 1562 | 38/M | p/nd | Dgn | 12 | 23 | 34,117,13,56, HLA-DR | Adverse1 | 1.79 | 9.9 | 190 | CR |
| 1564 | 68/M | p/M4 | Rel. | 72 | 70 | 34,117,13,33, 65,56, HLA-DR | Adverse1 | 21.7 | 8.8 | 65 | NCR | |
| 1574 | 56/M | s/nd | Dgn | 77 | 60 | 34, 117,15,19, HLA-DR | Adverse1 | 4.5 | 9.4 | 58 | NCR | |
| 1584 | 81/M | s/nd | Dgn | 40 | 82 | 15,65,56,33, HLA-DR | Adverse1 | 4.92 | 8.9 | 77 | NCR | |
| ALL | 1587 | 58/M | c/B-ALL | Dgn | 34 | 40 | 34,19,15,10,56, HLA-DR | High2 | 4.83 | 8.6 | 478 | NCR |
| 1588 | 62/M | c/B-ALL | Dgn | 1 | 18 | 34,19,56,20, HLA-DR | Standard2 | 1.74 | 11.9 | 186 | NCR | |
| 1605 | 57/F | c/B-ALL | Dgn | 80 | 78 | 34,19,20,22,10,56, HLA-DR | Highest2 | 133 | 12.1 | 76 | NCR | |
| CLL | 1589 | 84/M | p/B-CLL | Dgn | 30 | 71 | 5,19,20,15,23,56, HLA-DR | A3 | 10.15 | 15.3 | 142 | nd |
| 1591 | 76/F | p/B-CLL | Dgn | 52 | 30 | 5,19,15,20, HLA-DR | A3 | 23.46 | 13.5 | 203 | nd | |
| H | 1561 | 30/F | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd |
| 1566 | 29/F | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd | |
| 1576 | 56/M | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd | |
| 1582 | 29/M | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd |
AML acute myeloid leukemia; ALL acute lymphoid leukemia; CLL chronic lymphoid leukemia; H healthy donors; Pat. Nr. Patient’s number; F female; M male; p primary; s secondary; c: common; CD Cluster of differentiation; dgn first diagnosis; rel relapse; CR Complete remission; NCR no complete remission; pers. persisting disease; PLT platelets; WBC white blood cells; IC LC immune cytologically detected leukemic cells; ML LC morphologically detected leukemic cells in peripheral blood; nd no data.
1AML patients were prognostically classified based on the National Comprehensive Cancer Network (NCCN) guidelines as “favorable”, “intermediate” or “adverse risk”.
2Risk stratification for adult ALL was based on the Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) as “standard”, “high” or “highest risk”.
3According to Binet-classification, CLL patients were classified by Binet A, Binet B, Binet C. Bold blast markers were used for (co)expression analyses.